---
title: "Livzon Pharmaceutical Group Inc. (000513.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000513.SZ.md"
symbol: "000513.SZ"
name: "Livzon Pharmaceutical Group Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:41:01.830Z"
locales:
  - [en](https://longbridge.com/en/quote/000513.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000513.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000513.SZ.md)
---

# Livzon Pharmaceutical Group Inc. (000513.SZ)

## Company Overview

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.livzon.com.cn](https://www.livzon.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.33% |  |
| Net Profit YoY | -6.05% |  |
| P/B Ratio | 1.91 |  |
| Dividend Ratio | 3.55% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 27734188957.16 |  |
| Revenue | 11731568352.96 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.69% | B |
| Profit Margin | 16.77% | A |
| Gross Margin | 65.87% | A |
| Revenue YoY | -0.33% | D |
| Net Profit YoY | -6.05% | C |
| Total Assets YoY | -1.19% | D |
| Net Assets YoY | 1.35% | C |
| Cash Flow Margin | 164.90% | B |
| OCF YoY | -0.33% | D |
| Turnover | 0.48 | C |
| Gearing Ratio | 35.59% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Livzon Pharmaceutical Group Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.33%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-6.05%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.91",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.55%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "27734188957.16",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "11731568352.96",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.69%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "16.77%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "65.87%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.33%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-6.05%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.19%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.35%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "164.90%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-0.33%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "35.59%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.10 | 9/215 | 16.38 | 15.32 | 14.69 |
| PB | 1.91 | 77/215 | 2.55 | 2.34 | 2.25 |
| PS (TTM) | 2.36 | 52/215 | 2.99 | 2.75 | 2.61 |
| Dividend Yield | 3.55% | 23/215 | 3.38% | 3.10% | 2.81% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-26T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Hold | 1 | 20% |
| Sell | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 31.19 |
| Highest Target | 47.60 |
| Lowest Target | 25.52 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000513.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000513.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000513.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000513.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**